TOPADUR Pharma AG is a Swiss biopharmaceutical start-up based in Schlieren, Zurich. The company was founded in 2015 by experienced scientists that combine several years of expertise in R&D Pharma. We strive for significant improvement of patients’ quality of life while providing sustainable high growth value for investors and employees.About us
Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases. They stimulate capillary blood flow with unprecedented potency and efficacy, and address the problems caused by endothelial dysfunction.Our Approach
TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.Read More
Aging processes are characterized by a reduction in blood circulation and dysregulation in cell-cell communication. The misbalance of cGMP levels leads to diseases like chronic wounds, skin fibrosis, glaucoma, colorectal cancer, hair loss and skin aging.
TOPADUR designed new drugs that target the cGMP-Enzyme Regulation System. TOPADUR’s compounds regulate the activity of sGC and PDE5 enzymes to increase the level of cGMP. This ultimately enables blood circulation and corrects the insufficient cell-cell communication.
TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.Read more
TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.Read more